0001567619-22-012144.txt : 20220602
0001567619-22-012144.hdr.sgml : 20220602
20220602164807
ACCESSION NUMBER: 0001567619-22-012144
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220601
FILED AS OF DATE: 20220602
DATE AS OF CHANGE: 20220602
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Welgus Howard G.
CENTRAL INDEX KEY: 0001801050
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39186
FILM NUMBER: 22991538
MAIL ADDRESS:
STREET 1: C/O ARCUTIS BIOTHERAPEUTICS, INC.
STREET 2: 2945 TOWNSGATE ROAD, SUITE 110
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91361
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Arcutis Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001787306
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 812974255
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3027 TOWNSGATE ROAD
STREET 2: SUITE 300
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91361
BUSINESS PHONE: 805-418-5006
MAIL ADDRESS:
STREET 1: 3027 TOWNSGATE ROAD
STREET 2: SUITE 300
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91361
FORMER COMPANY:
FORMER CONFORMED NAME: Arcutis, Inc.
DATE OF NAME CHANGE: 20190905
4
1
doc1.xml
FORM 4
X0306
4
2022-06-01
0
0001787306
Arcutis Biotherapeutics, Inc.
ARQT
0001801050
Welgus Howard G.
C/O ARCUTIS BIOTHERAPEUTICS, INC.
3027 TOWNSGATE ROAD, SUITE 300
WESTLAKE VILLAGE
CA
91361
1
0
0
0
Common Stock
2022-06-01
4
M
0
2500
1.6806
A
184396
D
Common Stock
2022-06-01
4
S
0
2500
20.6154
D
181896
D
Common Stock
24991
I
By Trust
Stock Option (Right to Buy)
1.6806
2022-06-01
4
M
0
2500
0.00
D
2029-03-13
Common Stock
2500
41478
D
Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
Includes 4,500 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
The transaction was executed in multiple trades in prices ranging from $20.285 to $20.92, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The securities are held of record by The Welgus Living Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
The option began vesting on March 13, 2019 and will vest monthly over a four year period, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.
/s/ Scott Burrows, as Attorney-in-Fact for Howard G. Welgus
2022-06-02